Pharma & Biotech News Highlights Q3 2016
Following a quarter that featured reports stating that Novartis had dramatically redistributed its cell and gene therapy unit 1 and saw the public focus turn once again to drug price hikes, Pharma IQ brings you the pharma, biotech and life sciences news highlights for Q3 of 2016.Drug PricingMylan under media eye for Epi Pen pricing: This quarter Mylan. N.V was put in the hot-seat regarding the growing price tag attached to Epi Pens. The pharma firm faced intense criticism after calculations esti...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.